Recent Investment Analysts’ Ratings Updates for Illumina (ILMN)

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

• 8/5/2026 – Illumina was downgraded by Deutsche Bank Aktiengesellschaft to “hold”.
• 8/3/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $190.00 to $205.00. They now have a “hold” rating on the stock.
• 8/3/2026 – Illumina had its price target raised by Citigroup Inc. from $95.00 to $113.00. They now have a “sell” rating on the stock.
• 8/3/2026 – Illumina was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/3/2026 – Illumina had its “overweight” rating reaffirmed by Piper Sandler. They now have a $225.00 price target on the stock, up from $200.00.
• 8/1/2026 – Illumina was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/31/2026 – Illumina had its price target raised by Royal Bank Of Canada from $170.00 to $230.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Illumina had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $215.00 price target on the stock.
• 7/31/2026 – Illumina had its price target raised by Guggenheim from $200.00 to $226.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by Barclays PLC from $145.00 to $160.00. They now have an “underweight” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by JPMorgan Chase & Co. from $220.00 to $230.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by TD Cowen from $192.00 to $210.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by Stifel Nicolaus from $155.00 to $225.00. They now have a “buy” rating on the stock.
• 7/18/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Illumina had its price target raised by Leerink Partners from $175.00 to $210.00. They now have an “outperform” rating on the stock.
• 7/15/2026 – Illumina had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $140.00 to $190.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 7/1/2026 – Illumina had its price target raised by Piper Sandler from $170.00 to $200.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Illumina had its price target raised by Guggenheim from $180.00 to $200.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Illumina is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $185.00 price target on the stock.
• 6/25/2026 – Illumina was upgraded by Sanford C. Bernstein to “hold”.
• 6/24/2026 – Illumina had its price target raised by Barclays PLC from $122.00 to $145.00. They now have an “underweight” rating on the stock.

Insiders Place Their Bets

In other Illumina news, Director Keith A. Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock worth $255,966,311 in the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.